Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: case report.
Sorafenib is an oral tyrosine kinase inhibitor used in the treatment of metastatic hepatocellular carcinoma (HCC). Its common adverse reactions include diarrhea, hand-foot syndrome, rash, cardiac ischemia or infarction, hypertension, elevated serum lipase and hypophosphatemia. A 35-year-old male pat...
| Publicado en: | Turkiye Klinikleri Journal of Medical Sciences Vol. 32; no. 2; pp. 585 - 588 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | case study Journal Article |
| Publicado: |
Turkiye Klinikleri
Apr2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |